Pricing & Reimbursement

show blocks helper

Sort by Price
- Default Order
- Name
- Price
- Date
- Popularity

Click to order products ascending

Display 15 Products per page

US Pricing and Reimbursement

$2,995.00

Historically, few pricing controls have been implemented in the US; however, there is greater pressure to implement controls to help contain costs associated with the expansion of public healthcare provision.
November 2, 2016
Select options
NOACs Pricing, Reimbursement, and Access

$2,995.00

A combination of the high cost of novel oral anticoagulants (NOACs) (relative to highly genericized vitamin K antagonists) and the large patient populations these drugs address, has resulted in this class of compounds being a top priority for European payers.
May 10, 2017
Select options
Chronic Heart Failure Pricing, Reimbursement, and Access

$2,995.00

Payers were originally extremely worried about the potential cost burden of Entresto, however, the level of concern surrounding the drug is currently moderate as physician uptake has been lower than expected.
April 13, 2018
Select options
Germany Pricing and Reimbursement

$2,995.00

The German pharmaceutical market has historically been the most attractive European market due to high prices and high drug utilization. However, this is changing, with comparability assessment requirement raising the bar for achieving a higher price point.
November 2, 2016
Select options
Drug Pricing in the US

$2,995.00

Drug prices in the US have been the subject of intense debate over the past 2–3 years, following a surge in spending on prescription medicines and steep price increases in some categories
July 5, 2017
Select options
Renal Cell Cancer Pricing, Reimbursement, and Access

$2,995.00

There is moderate concern among payers regarding spend on renal cell cancer (RCC) drugs, but access restrictions remain mild.
August 22, 2018
Select options
Access in Emerging Markets: HTA is Making Inroads

$2,995.00

Generally considered the domain of developed markets, health technology assessment (HTA) is increasingly being used by developing countries as a means of reconciling growing demand for access to health technologies with limited resources. Expanding public health insurance programs, coupled with aging populations and growing patient empowerment, have led in some cases to the fast establishment […]
November 2, 2016
Select options
Type 2 Diabetes Pricing, Reimbursement, and Access

$2,995.00

Increased competition in the type 2 diabetes market resulting from multiple product launches in the same class and biosimilar competition is providing payers with opportunities to contain costs in the category that accounts for a significant proportion of total drug costs.
February 6, 2017
Select options
Bladder Cancer Pricing, Reimbursement, and Access

$2,995.00

Payers are not overly worried about the cost of bladder cancer, due to the relatively small patient population in comparison to other solid tumors.
September 27, 2018
Select options
Hemophilia Pricing, Reimbursement, and Access

$2,995.00

Over the last two decades, clinical care of hemophilia has improved significantly, extending the life expectancy for this patient population closer to that of the general population. The emergence of virally inactivated plasma-derived clotting factors and then of recombinant clotting factor replacement therapy in the 1980s has revolutionized care for these patients.
January 18, 2017
Select options
HR+/HER2- Breast Cancer Pricing, Reimbursement, and Access

$2,995.00

Despite a high level of concern regarding spend on breast cancer medicines, access restrictions remain only mild to moderate. Spend in the indication is in the top three in oncology due to both medicines’ cost and high disease prevalence
October 16, 2018
Select options
HER2+ Breast Cancer Pricing and Reimbursement

$2,995.00

Despite their high prices, Kadcyla and Perjeta are widely reimbursed in the US and have experienced fast uptake as payers have limited options for cost control in this indication.
November 4, 2016
Select options
Multiple Sclerosis Pricing, Reimbursement, and Access

$2,995.00

The multiple sclerosis (MS) market access landscape is becoming more challenging for drug manufacturers due to an increasing number of treatment modalities in the relapsing forms of MS. For the relapsing indications, payers are attempting to leverage the breadth of options by engaging in rebate contracts.
July 25, 2017
Select options
Managed Entry Agreements

$2,995.00

Managed entry agreements (MEAs) describe a range of mechanisms by which pharmaceutical firms and payers share some of the financial and clinical risk associated with the introduction of a new medicine.
November 4, 2016
Select options
Rheumatoid Arthritis Pricing, Reimbursement, and Access

$2,995.00

Increased competition in the rheumatoid arthritis (RA) market resulting from biosimilar competition and the launch of me-too interleukin (IL) drugs give payers leverage to enact cost-containment measures for a drug category that has experienced high unit cost increases year over year.
April 4, 2017
Select options

Pricing & Reimbursement

US Pricing and Reimbursement

NOACs Pricing, Reimbursement, and Access

Chronic Heart Failure Pricing, Reimbursement, and Access

Germany Pricing and Reimbursement

Drug Pricing in the US

Renal Cell Cancer Pricing, Reimbursement, and Access

Access in Emerging Markets: HTA is Making Inroads

Type 2 Diabetes Pricing, Reimbursement, and Access

Bladder Cancer Pricing, Reimbursement, and Access

Hemophilia Pricing, Reimbursement, and Access

HR+/HER2- Breast Cancer Pricing, Reimbursement, and Access

HER2+ Breast Cancer Pricing and Reimbursement

Multiple Sclerosis Pricing, Reimbursement, and Access

Managed Entry Agreements

Rheumatoid Arthritis Pricing, Reimbursement, and Access